A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Public ClinicalTrials.gov record NCT04529772. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤75 Years With Previously Untreated Non-GCB DLBCL
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.
Study identification
- NCT ID
- NCT04529772
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 611 participants
Conditions and interventions
Conditions
Interventions
- acalabrutinib Drug
- placebo Drug
- Prednisone Drug
- Rituximab Drug
- Cyclophosphamide Drug
- Vincristine Drug
- Doxorubicin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 8, 2020 (Actual)
- Primary completion
- Feb 22, 2027 (Estimated)
- Completion
- Feb 22, 2027 (Estimated)
- Last update posted
- Oct 13, 2026
2020 – 2027
United States locations
- U.S. sites
- 32
- U.S. states
- 21
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tucson | Arizona | 85711 | — |
| Research Site | Little Rock | Arkansas | 72205 | — |
| Research Site | Irvine | California | 92618 | — |
| Research Site | Aurora | Colorado | 80012 | — |
| Research Site | Norwich | Connecticut | 06360 | — |
| Research Site | Fort Myers | Florida | 33901 | — |
| Research Site | Orlando | Florida | 32804 | — |
| Research Site | St. Petersburg | Florida | 33705-1449 | — |
| Research Site | Tallahassee | Florida | 32308-5304 | — |
| Research Site | West Palm Beach | Florida | 33401 | — |
| Research Site | Fort Wayne | Indiana | 46845 | — |
| Research Site | Des Moines | Iowa | 50309 | — |
| Research Site | Wichita | Kansas | 67214 | — |
| Research Site | Louisville | Kentucky | 40207 | — |
| Research Site | Baltimore | Maryland | 21201 | — |
| Research Site | Grand Rapids | Michigan | 49503 | — |
| Research Site | Minneapolis | Minnesota | 55407 | — |
| Research Site | St Louis | Missouri | 63129 | — |
| Research Site | Albany | New York | 12208 | — |
| Research Site | New York | New York | 10028 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Stony Brook | New York | 11795 | — |
| Research Site | Charlotte | North Carolina | 28204 | — |
| Research Site | Winston-Salem | North Carolina | 27103 | — |
| Research Site | Eugene | Oregon | 97401 | — |
| Research Site | Portland | Oregon | 97239 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
| Research Site | Pittsburgh | Pennsylvania | 15212 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Fort Sam Houston | Texas | 78234 | — |
| Research Site | Lubbock | Texas | 79410 | — |
| Research Site | Salem | Virginia | 24153 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 213 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04529772, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2026 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04529772 live on ClinicalTrials.gov.